At a glance
A combined research record involving a CJC-1295 formulation and GHRP-2.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together a CJC-1295 formulation and GHRP-2. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[1][3][6]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][2][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of CJC-1295 + GHRP-2.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 2 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 150 mcg (0.15 mg) | 4.5 units (0.045 mL) |
| Weeks 3–12 | 300 mcg (0.30 mg) | 9 units (0.09 mL) |
Frequency: Tie timing to the research design. Human work supports acute synergistic GH release when GHRH and a growth hormone-releasing peptide are combined[6]. The cited study used controlled intravenous administration and does not define a bedtime subcutaneous schedule for this exact blend.
Advanced / Twice-Daily Approach (3 mL = ~3.33 mg/mL)
| Week | Dose per Injection (mcg) | Units (per injection) (mL) | Total Daily (mcg) |
|---|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 3 units (0.03 mL) | 200 mcg |
| Weeks 3–12 | 150 mcg (0.15 mg) | 4.5 units (0.045 mL) | 300 mcg |
Some protocols split the daily dose into two administrations (morning upon waking, fasted; and evening before bed) to enhance GH pulsatility[1]. Ensure doses are at least 3–8 hours apart to avoid overlapping GH pulses. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Support enhanced GH pulsatility and sustained IGF-1 elevation over a defined research period[1].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg daily (total blend) with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100–150 mcg daily for Weeks 1–2 to allow acclimatization[2].
- Target: 250–300 mcg daily by Weeks 3–12.
- Frequency: Once per day (subcutaneous), preferably evening/bedtime.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Inject on an empty stomach; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[9][10].
- Lyophilized: Refrigerate at 2–8 °C (35.6–46.4 °F); freeze at −20 °C (−4 °F) for long-term storage exceeding several months.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks for optimal potency.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- If longer storage of reconstituted solution is needed, aliquot into sterile containers and freeze once; avoid repeated freeze–thaw.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[7][8].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[8].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid local tissue changes[10].
- Withdraw the needle at the same angle; dispose immediately in a sharps container.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration (once-daily schedule).
-
Peptide Vials (CJC-1295 + GHRP-2, 10 mg each):
- 8 weeks ≈ 2 vials
- 12 weeks ≈ 3 vials
- 16 weeks ≈ 4 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
J Clin Endocrinol Metab (1998) — Mericq V et al. Effects of eight months treatment with graded doses of GHRP in GH-deficient children (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
J Clin Endocrinol Metab (1998) — Pihoker C et al. Pharmacokinetics and pharmacodynamics of GHRP-2: a phase I study in children (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
J Clin Endocrinol Metab (2005) — Laferrère B et al. GHRP-2, like ghrelin, increases food intake in healthy men (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
Peptides (1997) — Arvat E et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH, and cortisol levels in man (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 07
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 09
Source document
Bachem Technical Bulletin — Handling and storage guidelines for peptides (opens in a new tab)www.bachem.com
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.